scholarly journals Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation

2016 ◽  
Vol 36 (12) ◽  
pp. 6439-6448 ◽  
Author(s):  
TIMO JOENSUU ◽  
GREETTA JOENSUU ◽  
KALEVI KAIREMO ◽  
TIMO KILJUNEN ◽  
MAIGO RIENER ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Primary Treatment ◽  
Androgen Deprivation

scholarly journals Androgen deprivation and immunotherapy for the treatment of prostate cancer

2017 ◽  
Vol 24 (12) ◽  
pp. T297-T310 ◽  
Author(s):  
Melissa Gamat ◽  
Douglas G McNeel
Keyword(s):  
Prostate Cancer ◽  
Immune System ◽  
Metastatic Prostate Cancer ◽  
The United States ◽  
Primary Treatment ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Recurrent Prostate Cancer ◽  
System A ◽  
Different Types

Prostate cancer is the most common newly diagnosed malignancy in men, and the second most common cause of cancer-related death in the United States. The primary treatment for recurrent prostate cancer is androgen deprivation, and this therapy is typically continued lifelong for patients with metastatic prostate cancer. Androgens and androgen deprivation have profound effects on the immune system, a finding that has become more appreciated in an era where immune-based treatments for cancer are being increasingly explored. Preclinical studies suggest that androgen deprivation could potentially positively or negatively affect the use of approved immunotherapies, or those that are being developed for the treatment of prostate cancer. In this review, we provide a brief overview of the different types of androgen deprivation treatments used in the management of prostate cancer, discuss their effects on prostate tumors and the immune system and how they are being explored in combination with immunotherapy. Finally, we address some of the critical questions in the field that must be answered to identify the best approaches to combine androgen deprivation with immunotherapy for the treatment of prostate cancer.

scholarly journals Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer

Cancer ◽  
2018 ◽  
Vol 125 (3) ◽  
pp. 453-462 ◽  
Author(s):  
Hala T. Borno ◽  
Daphne Y. Lichtensztajn ◽  
Scarlett L. Gomez ◽  
Nynikka R. Palmer ◽  
Charles J. Ryan
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation

A proposed link between spinal epidural lipomatosis, prostate cancer and androgen deprivation therapy

2017 ◽  
Vol 11 (4) ◽  
pp. 299-301 ◽  
Author(s):  
Isabel Tulloch ◽  
James T Laban ◽  
Andrew J Martin
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Spastic Paraparesis ◽  
Androgen Deprivation ◽  
Vertebral Metastases ◽  
Spinal Epidural Lipomatosis ◽  
Epidural Lipomatosis ◽  
Spinal Epidural

We present a patient with prostate cancer with vertebral metastases who developed spastic paraparesis secondary to spinal epidural lipomatosis (SEL) after receiving androgen deprivation therapy (ADT). We propose a link between ADT, metastatic prostate cancer and SEL.

Management of Metastatic Castrate-sensitive Prostate Cancer

2018 ◽  
Author(s):  
Derya Tilki ◽  
Marc A Dall’era ◽  
Christopher P Evans
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Survival Benefit ◽  
Metastatic Prostate Cancer ◽  
Oncologic Outcome ◽  
Standard Of Care ◽  
Abiraterone Acetate ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Treatment Paradigm

Oncologic outcome of patients with newly diagnosed metastatic prostate cancer (mPCa) is poor. The treatment paradigm for newly diagnosed mPCa has changed. The standard of care for men with metastatic hormone-naive prostate cancer has been systemic androgen deprivation therapy (ADT). Previous randomized studies demonstrated an overall survival benefit by the addition of early chemotherapy with six cycles of docetaxel. More recently, results from randomized trials also demonstrated a survival benefit by the addition of abiraterone acetate to the ADT in men with metastatic disease. The aim of this review is to summarize the results from most recent studies, including men with newly diagnosed metastatic hormone-naive prostate cancer, focusing on chemotherapy and ADT. This review contains 1 figure, 2 tables, and 47 references.  Key Words: abiraterone acetate, androgen deprivation therapy, androgen deprivation, castrate sensitive, chemotherapy, continuous androgen deprivation, docetaxel, hormone-naive, intermittent androgen deprivation, metastatic prostate cancer

Sign in / Sign up

Export Citation Format

Share Document